TL;DR
- Debarment and disqualification are both FDA actions that bar a person or firm from participating in FDA-regulated work, but they come from different statutes, cover different populations, and have different legal effects (FDA: Debarment; FDA: Disqualified/Restricted/Assurance List).
- Debarment under Section 306 of the FD&C Act (21 U.S.C. § 335a) generally applies to companies and individuals convicted of drug-related crimes, and it bars them from providing services to any drug company that has an approved or pending drug application.
- Disqualification under 21 CFR 312.70 (drugs) and 21 CFR 812.119 (devices) targets clinical investigators specifically, for repeatedly or deliberately violating investigator obligations or submitting false data in a study.
- A debarred person cannot work for a drug sponsor in almost any capacity; a disqualified investigator can generally still practice medicine, they just cannot receive investigational products or conduct FDA-regulated clinical trials.
FDA Debarment vs. Disqualification: What's the Difference?
Both terms describe FDA barring someone from a role in the regulated industry, and both show up in due-diligence checks and compliance risk registers, which is exactly why they get confused. They are not interchangeable. Debarment is a criminal-conviction-triggered bar tied to Section 306 of the Federal Food, Drug, and Cosmetic Act, aimed mostly at companies and executives. Disqualification is a data-integrity and human-subject-protection tool aimed specifically at clinical investigators who ran a study badly or dishonestly (FDA: Debarment).
What Is FDA Debarment?
Debarment is governed by Section 306 of the FD&C Act (21 U.S.C. § 335a) and implementing regulations at 21 CFR Part 1404 (procedural rules shared across federal agencies) and FDA's own debarment regulations. There are two tracks: mandatory debarment, which follows a felony conviction related to the development or approval of a drug product or for bribery, fraud, or other listed offenses connected to a drug application, and permissive debarment, which FDA can pursue for certain misdemeanor convictions or other misconduct connected to regulated drug activity (FDA: Debarment).
The practical effect is broad: a debarred individual or company generally cannot provide services in any capacity to a person that has an approved or pending drug product application, and a sponsor that knowingly uses a debarred person's services risks its own drug applications. FDA publishes and updates a debarred list specifically because sponsors are expected to screen against it before hiring or contracting.
What Is FDA Disqualification?
Disqualification is a narrower, investigator-specific tool. For drugs, it's governed by 21 CFR 312.70; for devices, by 21 CFR 812.119. FDA can disqualify a clinical investigator who has "repeatedly or deliberately" failed to comply with investigator obligations under the applicable regulations, or who has submitted false information to the sponsor in connection with a study (FDA: Disqualified/Restricted/Assurance List).
Disqualification does not bar someone from practicing medicine or from working in the industry generally — it specifically bars them from receiving investigational new drugs or devices and from conducting FDA-regulated clinical investigations. Before a full disqualification, FDA typically pursues progressively serious steps: an informal Bioresearch Monitoring (BIMO) inspection notice-of-initiation-of-disqualification-proceedings (NIDPOE) letter, an opportunity to explain or correct, and only then a disqualification order if the issues aren't resolved.
Debarment vs. Disqualification, Side by Side
| Debarment | Disqualification | |
|---|---|---|
| Statutory basis | FD&C Act § 306 (21 U.S.C. § 335a) | 21 CFR 312.70 (drugs), 21 CFR 812.119 (devices) |
| Who it targets | Companies and individuals, often executives | Clinical investigators specifically |
| Trigger | Criminal conviction related to drug regulation | Repeated/deliberate violations or false data in a study |
| Scope of the bar | Broad — cannot provide services to any drug applicant | Narrow — cannot receive investigational products or run FDA-regulated trials |
| Can still practice medicine/work in industry generally | Not in a drug-related capacity | Generally yes, outside of FDA-regulated research |
FAQ
Can a debarred person ever work in the drug industry again?
Debarment can be for a fixed term or permanent depending on the offense, and FDA regulations provide a process to petition for termination of debarment after the applicable period, though approval isn't automatic (FDA: Debarment).
Does disqualification mean a doctor did something illegal?
Not necessarily criminal — disqualification is a regulatory finding about study conduct, such as failing to follow the investigational plan or protecting human subjects adequately, or submitting false data. It's a separate track from criminal prosecution, though the two can overlap in serious cases.
Is there a list companies are expected to check before hiring?
Yes for debarment — FDA maintains a public debarment list, and companies are expected to screen new hires and contractors against it before they perform any service related to a drug application (FDA: Debarment). FDA separately maintains the disqualified/restricted/assurance list for clinical investigators.
Can a disqualified investigator get requalified?
Yes, 21 CFR 312.70 provides a process for FDA to reinstate an investigator's eligibility if they present adequate assurance that they'll comply with requirements going forward, though FDA's decision is discretionary.
Related reading
- What Are the Six Rungs of FDA's Enforcement Escalation Ladder?
- What is an FDA Import Alert, and what does DWPE mean?
- What's the difference between a Form 483 and an FDA Warning Letter?
Sources: FDA: Debarment, FDA: Disqualified/Restricted/Assurance List, 21 CFR Part 312 (eCFR), 21 CFR Part 812 (eCFR). Byline: The Argus Regulatory Analysis Team. Published 2026-07-16.